New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Pragmatica-Lung Study aims to increase accessibility to cancer clinical trials

Pragmatica-Lung Study aims to increase accessibility to cancer clinical trials

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with adv
World medicine November 23,2023
Pragmatica-Lung Study aims to increase accessibility to cancer clinical trials

Pragmatica-Lung Study aims to increase accessibility to cancer clinical trials

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with adv
World medicine November 23,2023
CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

August 21, 2023Courtney FlahertyMarios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotligh
World medicine November 23,2023
CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

August 21, 2023Courtney FlahertyMarios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotligh
World medicine November 23,2023
Digital breast tomosynthesis improves cancer screening performance in community practice

Digital breast tomosynthesis improves cancer screening performance in community practice

Researchers have found that digital breast tomosynthesis (DBT) has improvedbreast cancer screeningperformance in community practice and identifies more invasive cancers, compared to digita
World medicine November 23,2023
Digital breast tomosynthesis improves cancer screening performance in community practice

Digital breast tomosynthesis improves cancer screening performance in community practice

Researchers have found that digital breast tomosynthesis (DBT) has improvedbreast cancer screeningperformance in community practice and identifies more invasive cancers, compared to digita
World medicine November 23,2023
Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

October 11, 2023Kristi RosaThe addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myelo
World medicine November 23,2023
Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

October 11, 2023Kristi RosaThe addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myelo
World medicine November 23,2023
Biomarker signature test can predict tumor response to bladder cancer immunotherapy

Biomarker signature test can predict tumor response to bladder cancer immunotherapy

In a discovery that could improve the survival of bladder cancer patients, Northwestern Medicine scientists have developed a biomarker signature test to predict which tumors will respond to immunother
World medicine November 23,2023
Biomarker signature test can predict tumor response to bladder cancer immunotherapy

Biomarker signature test can predict tumor response to bladder cancer immunotherapy

In a discovery that could improve the survival of bladder cancer patients, Northwestern Medicine scientists have developed a biomarker signature test to predict which tumors will respond to immunother
World medicine November 23,2023
Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

October 21, 2023Benjamin SaylorBelzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with t
World medicine November 23,2023
Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

October 21, 2023Benjamin SaylorBelzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with t
World medicine November 23,2023
Using an implantable nanofluidic device to tame pancreatic cancer

Using an implantable nanofluidic device to tame pancreatic cancer

Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer - one of the most aggressive and difficult to treat cancers - by delivering immunotherapy directly into the tumor
World medicine November 23,2023
Using an implantable nanofluidic device to tame pancreatic cancer

Using an implantable nanofluidic device to tame pancreatic cancer

Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer - one of the most aggressive and difficult to treat cancers - by delivering immunotherapy directly into the tumor
World medicine November 23,2023
Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC

Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC

August 28, 2023Megan HollaschLyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.Lyudmila A. Bazhenova, MDDes
World medicine November 23,2023
Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC

Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC

August 28, 2023Megan HollaschLyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.Lyudmila A. Bazhenova, MDDes
World medicine November 23,2023
Fatty liver promotes the spread of colorectal cancer to the liver

Fatty liver promotes the spread of colorectal cancer to the liver

Investigators at Cedars-Sinai Cancer found that fatty liver, a condition closely associated with obesity, promotes the spread of colorectal cancer to the liver. Their study, published today in the pee
World medicine November 23,2023
Fatty liver promotes the spread of colorectal cancer to the liver

Fatty liver promotes the spread of colorectal cancer to the liver

Investigators at Cedars-Sinai Cancer found that fatty liver, a condition closely associated with obesity, promotes the spread of colorectal cancer to the liver. Their study, published today in the pee
World medicine November 23,2023
OncoAssure announces results of clinical study on novel prostate cancer test

OncoAssure announces results of clinical study on novel prostate cancer test

OncoAssure today announced that results of its clinical study validating OncoAssure Prostate, a novel test for prostate cancer management, have been published in European Urology Focus, a peer-reviewe
World medicine November 23,2023
OncoAssure announces results of clinical study on novel prostate cancer test

OncoAssure announces results of clinical study on novel prostate cancer test

OncoAssure today announced that results of its clinical study validating OncoAssure Prostate, a novel test for prostate cancer management, have been published in European Urology Focus, a peer-reviewe
World medicine November 23,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com